Although AbbVie has lost patent exclusivity for its flagship drug, Humira, the company may soon be bigger and better.

Pharmaceutical powerhouse AbbVie (NYSE: ABBV) has been a beast since it spun off from Abbott Laboratories in 2012. Over the past decade, the stock has averaged a dividend yield of 3.5% while ...

AbbVie (NYSE: ABBV) could be the poster child for how to effectively navigate a patent cliff. When Abbott Labs spun off ...

We recently compiled a list of the 10 Best Halal Dividend Stocks To Invest In. In this article, we are going to take a look ...

The Dividend Kings underperformed in 2024. Read here to know about the top 18 most opportune Dividend Kings based on ...

This month, we explore the 125-year-old history of Abbott Laboratories and its most significant milestone to date – the creation of its own independent company, AbbVie. In 1888, a 30-year-old ...

When Abbott Labs spun off AbbVie in 2013, the latter heavily relied on its top-selling drug, Humira. However, in recent years, sales declined due to competition from biosimilars. AbbVie ...

The Main Stage on the show floor will host daily programming featuring thought leadership sessions, expert panels and the ...

While the Chicago metropolitan area is not a major life sciences hub, a recent Cushman & Wakefield report predicts the Chicago market should be a growth spot in the coming years. Chicago Biomedical ...

Discover how to navigate inflation with long-term investments in resilient companies like Coca-Cola, AbbVie, and TC Energy.